Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.53 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
| ▸ | TPH1 | P17752 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289162 | 1.00 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL180332 | 1.00 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL26747607 | 0.87 | ITGB3 (0.41) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL1932906 | 0.87 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL169645 | 0.87 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL169646 | 0.87 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL7381598 | 0.85 | ITGB3 (0.67) | SLC7A5ITGB3ITGA2BITGAVALDH1A1 | |
| SCHEMBL7453923 | 0.85 | ITGB3 (0.67) | SLC7A5ITGB3ITGA2BITGAVALDH1A1 | |
| SCHEMBL6378833 | 0.84 | LTA4H (0.48) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8423623 | 0.84 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626479-A1 | COMPOSITIONS AND METHODS FOR PROTEIN INTERNALIZATION | Lytica Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | claimed |
| EP-4522221-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS | Entrada Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| US-20240360177-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | AIMMAX THERAPEUTICS, INC. | 2024-10-31 | — | — | US | claimed |
| EP-4396196-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | Aimmax Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| WO-2024119049-A1 | COMPOSITIONS AND METHODS FOR PROTEIN INTERNALIZATION | LYTICA THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| EP-4359006-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | Entrada Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| CN-117957022-A | Antisense compounds and methods for targeting CUG repeats | 安卓达治疗股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117915957-A | Compositions and methods for modulating mRNA splicing | 恩特拉达治疗学股份有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117897394-A | Peptides with antimicrobial activity | 美商安满药物开发公司 | 2024-04-16 | — | — | CN | claimed |
| EP-4337263-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITY | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2005042565-A2 | CYCLIN GROOVE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | claimed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | claimed |
| US-5990084-A | A SERIES OF TRUNCATED ANALOGS OF HGHRH (HUMAN GROWTH HORMONE RELEASING HORMONE); ANALOG ACTIVATES THE GHRH RECEPTOR, BUT HAS IMPROVED METABOLIC STABILITY, DECREASED IMMUNOGENICITY AND LOWER COST OF PRODUCTION | NOVO NORDISK A/S (DK) | 1999-11-23 | — | — | US | claimed |
| EP-0910579-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-04-28 | — | — | EP | claimed |
| US-5874472-A | Aminoacid derivatives as no synthase inhibitors | GLAXO WELLCOME INC. (US) | 1999-02-23 | — | — | US | claimed |
| EP-0705257-B1 | AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS | WELLCOME FOUND (GB) | 1998-03-11 | — | — | EP | claimed |
| WO-1997040071-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| EP-0705257-A1 | AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-04-10 | — | — | EP | claimed |
| WO-1995000505-A1 | AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-01-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360177-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | VIP, FPR2, FPR1 | SLC7A5 3654/4885PTGS1 1799/4885ALPI 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.